As of December 15, 2025, Dexcom Inc (DXCM) reports a Gross Margin of 61.78%.
Gross Margin indicates the portion of sales revenue remaining after covering production costs, highlighting operational efficiency.
Historical Trend of Dexcom Inc's Gross Margin
Over recent years, Dexcom Inc's Gross Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Gross Margin |
|---|---|
| 2024-12-31 | 61.78% |
| 2023-12-31 | 63.65% |
| 2022-12-31 | 65.19% |
| 2021-12-31 | 69.78% |
| 2020-12-31 | 67.71% |
This slight downward trend highlights how Dexcom Inc manages its operational efficiency and pricing power over time.
Comparing Dexcom Inc's Gross Margin to Peers
To better understand Dexcom Inc's position, it's useful to compare its Gross Margin against industry peers. Below are selected comparisons:
| Company | Gross Margin |
|---|---|
| Dexcom Inc (DXCM) | 61.78% |
| Inari Medical Inc (NARI) | 88.03% |
| Shockwave Medical Inc (SWAV) | 86.94% |
| ABIOMED Inc (ABMD) | 81.76% |
| Inmode Ltd (INMD) | 80.31% |
| Edwards Lifesciences Corp (EW) | 79.46% |
Compared to its competitors, Dexcom Inc's Gross Margin is about average compared to peers, indicating industry-standard operational efficiency.